Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

AMLX

Amylyx Pharmaceuticals (AMLX)

Amylyx Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:AMLX
DateTimeSourceHeadlineSymbolCompany
04/12/202423:30Business WireAmylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric HypoglycemiaNASDAQ:AMLXAmylyx Pharmaceuticals Inc
28/11/202401:00Business WireAmylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx ConferenceNASDAQ:AMLXAmylyx Pharmaceuticals Inc
08/11/202400:22Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AMLXAmylyx Pharmaceuticals Inc
07/11/202423:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMLXAmylyx Pharmaceuticals Inc
07/11/202423:00Business WireAmylyx Pharmaceuticals Reports Third Quarter 2024 Financial ResultsNASDAQ:AMLXAmylyx Pharmaceuticals Inc
07/11/202411:24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
05/11/202401:00Business WireAmylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024NASDAQ:AMLXAmylyx Pharmaceuticals Inc
18/10/202400:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMLXAmylyx Pharmaceuticals Inc
18/10/202400:00Business WireAmylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram SyndromeNASDAQ:AMLXAmylyx Pharmaceuticals Inc
16/10/202400:00Business WireAmylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024NASDAQ:AMLXAmylyx Pharmaceuticals Inc
04/10/202405:06PR Newswire (US)Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law FirmNASDAQ:AMLXAmylyx Pharmaceuticals Inc
03/10/202408:53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
03/10/202408:53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
03/10/202408:48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
26/09/202407:56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
17/09/202407:39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
10/09/202406:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
28/08/202422:30Business WireAmylyx Pharmaceuticals to Participate in Upcoming Investor ConferencesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
27/08/202408:49Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:AMLXAmylyx Pharmaceuticals Inc
12/08/202423:00Business WireAmylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer’s Disease Pathology and NeurodegenerationNASDAQ:AMLXAmylyx Pharmaceuticals Inc
08/08/202421:14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AMLXAmylyx Pharmaceuticals Inc
08/08/202421:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMLXAmylyx Pharmaceuticals Inc
08/08/202421:00Business WireAmylyx Pharmaceuticals Reports Second Quarter 2024 Financial ResultsNASDAQ:AMLXAmylyx Pharmaceuticals Inc
05/08/202423:00Business WireAmylyx Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024NASDAQ:AMLXAmylyx Pharmaceuticals Inc
02/08/202423:00Business WireAmylyx Pharmaceuticals Receives Orphan Drug Designation From the European Commission for AMX0035 for the Treatment of Wolfram SyndromeNASDAQ:AMLXAmylyx Pharmaceuticals Inc
19/07/202409:00PR Newswire (US)Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law FirmNASDAQ:AMLXAmylyx Pharmaceuticals Inc
10/07/202421:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMLXAmylyx Pharmaceuticals Inc
10/07/202421:00Business WireAmylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) with FDA Breakthrough Therapy DesignationNASDAQ:AMLXAmylyx Pharmaceuticals Inc
10/07/202406:01Business WireAmylyx Pharmaceuticals to Host Conference Call to Discuss the Acquisition of AvexitideNASDAQ:AMLXAmylyx Pharmaceuticals Inc
08/06/202406:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:AMLX

Your Recent History

Delayed Upgrade Clock